Inceptionr LLC Sells 5,008 Shares of Vericel Co. (NASDAQ:VCEL)

Inceptionr LLC lowered its stake in shares of Vericel Co. (NASDAQ:VCEL) by 44.8% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 6,177 shares of the biotechnology company’s stock after selling 5,008 shares during the quarter. Inceptionr LLC’s holdings in Vericel were worth $339,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. FMR LLC lifted its holdings in shares of Vericel by 1.0% during the third quarter. FMR LLC now owns 2,372,812 shares of the biotechnology company’s stock worth $100,251,000 after buying an additional 22,461 shares during the last quarter. Congress Asset Management Co. lifted its holdings in shares of Vericel by 12.6% during the fourth quarter. Congress Asset Management Co. now owns 1,454,139 shares of the biotechnology company’s stock worth $79,847,000 after buying an additional 162,419 shares during the last quarter. GW&K Investment Management LLC lifted its holdings in shares of Vericel by 2.4% during the fourth quarter. GW&K Investment Management LLC now owns 1,273,964 shares of the biotechnology company’s stock worth $69,953,000 after buying an additional 30,180 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Vericel by 0.8% during the third quarter. Geode Capital Management LLC now owns 1,154,053 shares of the biotechnology company’s stock worth $48,768,000 after buying an additional 9,613 shares during the last quarter. Finally, Geneva Capital Management LLC lifted its holdings in shares of Vericel by 61.4% during the third quarter. Geneva Capital Management LLC now owns 1,104,386 shares of the biotechnology company’s stock worth $46,660,000 after buying an additional 420,078 shares during the last quarter.

Insider Buying and Selling at Vericel

In other Vericel news, Director Robert L. Md Zerbe sold 2,500 shares of Vericel stock in a transaction on Wednesday, February 5th. The stock was sold at an average price of $62.50, for a total transaction of $156,250.00. Following the completion of the transaction, the director now directly owns 26,595 shares of the company’s stock, valued at approximately $1,662,187.50. This trade represents a 8.59 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Jonathan Siegal sold 1,092 shares of Vericel stock in a transaction on Wednesday, February 5th. The shares were sold at an average price of $61.99, for a total value of $67,693.08. Following the transaction, the insider now directly owns 1,206 shares of the company’s stock, valued at approximately $74,759.94. The trade was a 47.52 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 7,500 shares of company stock valued at $466,200. 5.20% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on VCEL shares. Stephens reiterated an “overweight” rating and set a $65.00 price target on shares of Vericel in a report on Wednesday, January 15th. BTIG Research upped their price target on Vericel from $56.00 to $66.00 and gave the stock a “buy” rating in a report on Tuesday, November 26th. HC Wainwright restated a “buy” rating and issued a $60.00 target price on shares of Vericel in a research note on Friday, February 28th. Canaccord Genuity Group raised their target price on Vericel from $64.00 to $67.00 and gave the stock a “buy” rating in a research report on Monday, February 3rd. Finally, Truist Financial reaffirmed a “buy” rating and issued a $61.00 target price (down from $67.00) on shares of Vericel in a research report on Monday, March 3rd. One analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $62.29.

Vericel Price Performance

Shares of VCEL stock opened at $49.56 on Monday. The stock has a market cap of $2.48 billion, a P/E ratio of 826.14 and a beta of 1.78. The stock has a fifty day moving average price of $56.48 and a 200 day moving average price of $51.98. Vericel Co. has a one year low of $39.12 and a one year high of $63.00.

Vericel Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.